SIRPA and mature T-cell and NK-cell non-Hodgkin lymphoma: As the TME in many PTCL's is permissive for LAM, alternative therapeutic approaches which seek to exploit LAM as effector cells, upon CD47/SIRPα blockade (39), for example, are certainly rational and effective in a minority of patients in early-phase clinical studies.